AbCellera Biologics Inc. (NASDAQ:ABCL)
| Market Cap | $3.16B+176.1% |
| Revenue (ttm) | $67.86M+92.1% |
| Net Income | -$148.29M+13.6% |
| EPS | -$0.48+17.2% |
| Shares Out | 326.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,235,023 |
| Open | $9.99 |
| Previous Close | $10.47 |
| Day's Range | $9.58 - $10.26 |
| 52-Week Range | $2.75 - $15.02 |
| Beta | 1.19 |
| Analysts | Buy |
| Price Target | $18.20(+87.82%) |
| Earnings Date | Feb 23, 2027 |
About ABCL
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
AbCellera Biologics Inc. Stock Analysis — InsiderScore
AbCellera Biologics Inc. scored higher than 62% of companies evaluated by InsiderBuying, and ranked 28th out of 101 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at AbCellera Biologics Inc. bought $667.9K of stock across 2 purchases in the last 90 days, the largest of them $570.4K.
The average purchase added about 2% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating ABCL in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 23, 2027Earnings report
$ABCL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ABCL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ABCL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ABCL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ABCL Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ABCL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ABCL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ABCL
| IBBiShares Biotechnology ETF | $20.24M |
| IDNAiShares Genomics Immunology and Healthcare ETF | $7.64M |
| SPDWState Street SPDR Portfolio Developed World ex-US ETF | $6.27M |
| FKOFirst Trust South Korea AlphaDEX Fund | $4.20M |
| FHKFirst Trust Hong Kong AlphaDEX Fund | $4.20M |
| FDTFirst Trust Developed Markets ex-US AlphaDEX Fund | $4.20M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ABCL’s recent data — informational, not investment advice
What’s Behind the Score
News check: AbCellera Q3 results showed revenue beats, narrowing losses, and promising hot flash trial advancement toward Phase 3, signaling positive clinical and financial momentum.
Recent Insider Activity
Insider Score Trend Over Time
-7.2 since Sep 23Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| IDNA | iShares Genomics Immunology and Healthcare ETF | 2.45% |
| NIFE | Direxion Fallen Knives ETF | 2.10% |
| BBC | Virtus Biotech Clinical Trials ETF | 1.69% |
| SILX | ETFMG Prime 2x Daily Junior Silver Miners ETF | 0.78% |
| FKO | First Trust South Korea AlphaDEX Fund | 0.37% |
| FAUS | First Trust Australia AlphaDEX Fund | 0.37% |
| FCAN | First Trust Canada AlphaDEX Fund | 0.37% |
| FDT | First Trust Developed Markets ex-US AlphaDEX Fund | 0.37% |
| FHK | First Trust Hong Kong AlphaDEX Fund | 0.37% |
| APXH | Two Roads Shared Trust - APEX HealthCare ETF | 0.25% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 0.24% |
| IBB | iShares Biotechnology ETF | 0.20% |
Weight is the stock’s share of each fund’s holdings.
